Tanja Ruokoranta
Helsinki, Finland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
NAMPT haploinsufficiency is a therapeutic vulnerability to NAMPT inhibition in -7/-7q MDS.
Journal: Biomarker research
Published: March 25, 2026
Early venetoclax dose escalation at minimal residual disease progression may benefit selected acute myeloid leukaemia patients.
Journal: British journal of haematology
Published: March 05, 2026
Drivers of clinical resistance to venetoclax and hypomethylating agents in acute myeloid leukemia and strategies for improving efficacy.
Journal: HemaSphere
Published: June 24, 2025
Capillary Sampling Enables Venetoclax Concentration Measurement in Acute Myeloid Leukaemia Within Academic Multicentre Trial.
Journal: Basic & clinical pharmacology & toxicology
Published: November 18, 2024
Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones.
Journal: Nature communications
Published: August 15, 2023
Designing patient-oriented combination therapies for acute myeloid leukemia based on efficacy/toxicity integration and bipartite network modeling.
Journal: Oncogenesis
Published: June 16, 2023
Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia.
Journal: Haematologica
Published: June 30, 2022
Coxsackievirus B1 infections are associated with the initiation of insulin-driven autoimmunity that progresses to type 1 diabetes.
Journal: Diabetologia
Published: October 25, 2017
Last Updated: 09/26/2026